close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Xenetic Biosciences, Inc. - Common Stock (NQ:XBIO)

2.530 -0.010 (-0.39%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Xenetic Biosciences, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform
Via ACCESS Newswire
News headline image
Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results
Via ACCESS Newswire
News headline image
Xenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common Stock
Via ACCESS Newswire
News headline image
MAGA Stocks Undercard: MYSE, XBIO, ATON, ACXP, RDZN – Innovators Driving Next Tech, Blockchain, AI Wave – More Stocks Inside
Via AB Newswire
Topics Artificial Intelligence Intellectual Property
News headline image
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
Via ACCESSWIRE
News headline image
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
Via ACCESSWIRE
News headline image
Xenetic Biosciences, Inc. Reports Second Quarter 2025 Financial Results
Via ACCESS Newswire
News headline image
Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Large B Cell Lymphoma
Via ACCESS Newswire
News headline image
Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform
Via ACCESS Newswire
News headline image
Xenetic Biosciences, Inc. Announces Update from Collaboration Partner of First Patient Dosed in Exploratory Clinical Study of DNase I in Combination with FOLFIRINOX for the First Line Treatment of Unresectable, Locally Advanced or Metastatic Pancreatic
Via ACCESS Newswire
News headline image
Xenetic Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update
Via ACCESS Newswire
News headline image
Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results
Via ACCESSWIRE
News headline image
Xenetic Biosciences, Inc. Extends Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform
Via ACCESSWIRE
News headline image
Xenetic Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update
Via ACCESSWIRE
News headline image
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
Via ACCESS Newswire
News headline image
Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and Ewing Sarcoma
Via ACCESS Newswire
News headline image
Xenetic Biosciences, Inc. Reports Full Year 2024 Financial Results
Via ACCESS Newswire
News headline image
Xenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic Responses
Via ACCESS Newswire
News headline image
Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting
Via ACCESS Newswire
News headline image
Xenetic Biosciences, Inc. Announces Executive Leadership Transition
Via ACCESSWIRE
News headline image
Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform
Via ACCESSWIRE
News headline image
Xenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology Program
Via ACCESSWIRE
News headline image
Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis
Via ACCESSWIRE
News headline image
Xenetic Biosciences, Inc. Presents Positive Data Demonstrating DNase I Significantly Improves Efficacy of Anti-CTLA-4 Immune Checkpoint Blockade in Preclinical Colorectal Carcinoma Models
Via ACCESSWIRE
News headline image
Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024
Via ACCESSWIRE
News headline image
Xenetic Biosciences, Inc. Enters into Materials Transfer Agreement with Tokyo Medical University for the Advancement of Its DNase-Based Oncology Platform
Via ACCESSWIRE
News headline image
Xenetic Biosciences, Inc. Presents at the H.C. Wainwright 26th Annual Global Investment Conference
Via ACCESSWIRE
News headline image
Xenetic Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
Via ACCESSWIRE
News headline image
Xenetic Biosciences, Inc. Reports Full Year 2023 Financial Results
Via ACCESSWIRE
News headline image
Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform
Via ACCESSWIRE
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today